贝瑞基因(000710) - 2024 Q3 - 季度财报

Revenue and Profit - The company's revenue for Q3 2024 was ¥270,888,226.55, representing a decrease of 11.16% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥1,122,665.08, an increase of 102.82% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,322,198.94, up 110.12% from the previous year[2] - Total operating revenue for Q3 2024 was CNY 822,664,528.62, a decrease of 4.9% compared to CNY 865,605,843.90 in the same period last year[11] - Net profit for Q3 2024 was CNY 13,944,517.00, a significant recovery from a net loss of CNY 133,132,588.87 in Q3 2023[12] - Earnings per share for Q3 2024 was CNY 0.0294, compared to a loss per share of CNY -0.3806 in the same quarter last year[13] Cash Flow and Investments - The operating cash flow net amount for the year-to-date was ¥22,902,746.34, reflecting a significant increase of 254.55% compared to the same period last year[2] - The cash flow from investment activities for the year-to-date was ¥61,868,308.34, a substantial increase of 290.00% compared to the previous year[6] - The net cash flow from operating activities for Q3 2024 was ¥22,902,746.34, an increase from ¥6,459,630.18 in Q3 2023, reflecting improved operational efficiency[15] - Total cash inflow from investment activities was ¥309,503,280.00, significantly higher than ¥6,975,472.22 in the same period last year[15] - The net cash flow from investment activities was ¥61,868,308.34, recovering from a negative cash flow of -¥32,561,751.58 in Q3 2023[15] - The net cash flow from financing activities was -¥198,514,158.84, compared to -¥24,003,979.53 in Q3 2023, showing increased cash outflows for debt repayment[15] Assets and Liabilities - Total assets as of September 30, 2024, were ¥2,539,381,428.92, a decrease of 7.36% from the end of the previous year[2] - The company's equity attributable to shareholders increased to ¥1,874,087,697.69, a slight increase of 0.54% from the end of the previous year[2] - The company has a total of ¥1,595,574,893.32 in current assets, up from ¥1,472,996,759.37, an increase of approximately 8.3%[10] - The total liabilities decreased to CNY 631,315,936.19 from CNY 846,563,923.36 year-over-year[11] - The company's total liabilities decreased to ¥1,595,574,893.32 from ¥1,472,996,759.37, indicating a reduction in financial obligations[10] Shareholder Information - The total number of common shareholders at the end of the reporting period was 45,379[7] - The number of shares held by the top ten shareholders includes 12.45% by Chengdu Tianxing Instrument Group Co., Ltd. and 9.05% by Gao Yang[7] Operational Efficiency - The company reported a significant reduction in investment losses, with losses of CNY -6,798,926.38 compared to CNY -36,623,949.88 in the previous year[12] - Other comprehensive income for Q3 2024 was CNY -480,248.25, contrasting with CNY 3,176,915.40 in the same period last year[12] - The company aims to enhance market expansion and product development strategies in the upcoming quarters[11] Costs and Expenses - Total operating costs decreased to CNY 765,979,082.06, down 16.0% from CNY 911,575,255.95 year-over-year[11] - The company experienced a 60.39% reduction in financial expenses, amounting to ¥4,277,173.84, primarily due to loan repayments[5] - The cash paid for taxes rose to ¥53,753,798.64, up from ¥35,887,850.74 in Q3 2023, reflecting higher tax obligations[15] - The cash paid to employees increased slightly to ¥243,297,014.96 from ¥240,871,875.29 year-over-year[15] Inventory and Receivables - Accounts receivable increased to ¥1,064,985,647.45 from ¥807,950,441.91, representing a growth of about 31.7%[9] - Inventory decreased to ¥193,549,175.50 from ¥229,302,829.83, a reduction of approximately 15.6%[10] Audit Information - The company has not undergone an audit for the Q3 2024 report, as indicated in the financial statements[16]